Successful engraftment of CSCs prevented systolic dysfunction in MI mice as evidenced by the decreases in ejection fraction and fraction shortening 2 weeks after surgery as compared with the PBS-treated MI group, but in mice that received Oct3/4 siRNA-treated CSCs there was no significant difference observed in LVEF and LVFS as compared with MI-PBS mice (Fig. 2c, d), indicating that Oct3/4-deficient CSCs failed to preserve LV contractility post MI. The gene discussed is POU5F1; the disease is myocardial infarction.